25 XP   0   0   10

Swedish Orphan Biovitrum AB (publ)
Buy, Hold or Sell?

Let's analyse Swedish Orphan Biovitrum AB (publ) together

PenkeI guess you are interested in Swedish Orphan Biovitrum AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Swedish Orphan Biovitrum AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Swedish Orphan Biovitrum AB (publ)

I send you an email if I find something interesting about Swedish Orphan Biovitrum AB (publ).

Quick analysis of Swedish Orphan Biovitrum AB (publ) (30 sec.)










What can you expect buying and holding a share of Swedish Orphan Biovitrum AB (publ)? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr101.38
Expected worth in 1 year
kr128.97
How sure are you?
85.0%

+ What do you gain per year?

Total Gains per Share
kr27.58
Return On Investment
10.3%

For what price can you sell your share?

Current Price per Share
kr267.20
Expected price per share
kr243.20 - kr302.00
How sure are you?
50%

1. Valuation of Swedish Orphan Biovitrum AB (publ) (5 min.)




Live pricePrice per Share (EOD)

kr267.20

Intrinsic Value Per Share

kr38.76 - kr273.10

Total Value Per Share

kr140.15 - kr374.48

2. Growth of Swedish Orphan Biovitrum AB (publ) (5 min.)




Is Swedish Orphan Biovitrum AB (publ) growing?

Current yearPrevious yearGrowGrow %
How rich?$3.2b$2.2b$489m17.8%

How much money is Swedish Orphan Biovitrum AB (publ) making?

Current yearPrevious yearGrowGrow %
Making money$65m$58.5m$6.4m10.0%
Net Profit Margin12.5%13.6%--

How much money comes from the company's main activities?

3. Financial Health of Swedish Orphan Biovitrum AB (publ) (5 min.)




What can you expect buying and holding a share of Swedish Orphan Biovitrum AB (publ)? (5 min.)

Welcome investor! Swedish Orphan Biovitrum AB (publ)'s management wants to use your money to grow the business. In return you get a share of Swedish Orphan Biovitrum AB (publ).

What can you expect buying and holding a share of Swedish Orphan Biovitrum AB (publ)?

First you should know what it really means to hold a share of Swedish Orphan Biovitrum AB (publ). And how you can make/lose money.

Speculation

The Price per Share of Swedish Orphan Biovitrum AB (publ) is kr267.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Swedish Orphan Biovitrum AB (publ).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Swedish Orphan Biovitrum AB (publ), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr101.38. Based on the TTM, the Book Value Change Per Share is kr6.90 per quarter. Based on the YOY, the Book Value Change Per Share is kr2.45 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Swedish Orphan Biovitrum AB (publ).

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.030.0%0.190.1%0.170.1%0.190.1%0.120.0%
Usd Book Value Change Per Share1.680.6%0.650.2%0.230.1%0.360.1%0.210.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.680.6%0.650.2%0.230.1%0.360.1%0.210.1%
Usd Price Per Share21.00-20.94-19.86-18.47-14.78-
Price to Earnings Ratio201.79-78.67-40.23-42.43-64.03-
Price-to-Total Gains Ratio12.52-64.07-102.71--13.17--134.26-
Price to Book Ratio2.20-2.61-2.98-3.37-5.25-
Price-to-Total Gains Ratio12.52-64.07-102.71--13.17--134.26-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share25.1168
Number of shares39
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.650.36
Usd Total Gains Per Share0.650.36
Gains per Quarter (39 shares)25.2814.00
Gains per Year (39 shares)101.1255.99
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101019105646
202021920112102
303032930168158
404043940224214
505064950280270
606075960336326
707086970392382
808097980448438
909108990504494
100101110000560550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%36.04.00.090.0%42.017.00.071.2%
Book Value Change Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%34.06.00.085.0%41.015.03.069.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.059.00.0%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%34.06.00.085.0%41.015.03.069.5%

Fundamentals of Swedish Orphan Biovitrum AB (publ)

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

Fundamental data was last updated by Penke on 2024-03-13 02:38:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Swedish Orphan Biovitrum AB (publ).

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Swedish Orphan Biovitrum AB (publ) earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 1.8% means that kr0.02 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 1.8%. The company is making a profit. +1
  • The TTM is 12.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ1.8%TTM12.5%-10.7%
TTM12.5%YOY13.6%-1.1%
TTM12.5%5Y16.7%-4.2%
5Y16.7%10Y12.7%+4.0%
1.1.2. Return on Assets

Shows how efficient Swedish Orphan Biovitrum AB (publ) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.1% Return on Assets means that Swedish Orphan Biovitrum AB (publ) generated kr0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.1%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.1%TTM1.3%-1.1%
TTM1.3%YOY1.3%0.0%
TTM1.3%5Y1.6%-0.4%
5Y1.6%10Y1.6%+0.1%
1.1.3. Return on Equity

Shows how efficient Swedish Orphan Biovitrum AB (publ) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.3% Return on Equity means Swedish Orphan Biovitrum AB (publ) generated kr0.00 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.3%TTM2.5%-2.3%
TTM2.5%YOY2.6%-0.1%
TTM2.5%5Y3.6%-1.1%
5Y3.6%10Y3.1%+0.5%

1.2. Operating Efficiency of Swedish Orphan Biovitrum AB (publ).

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Swedish Orphan Biovitrum AB (publ) is operating .

  • Measures how much profit Swedish Orphan Biovitrum AB (publ) makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 10.6% means the company generated kr0.11  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 10.6%. The company is operating less efficient.
  • The TTM is 19.9%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ10.6%TTM19.9%-9.3%
TTM19.9%YOY17.1%+2.8%
TTM19.9%5Y22.3%-2.4%
5Y22.3%10Y18.5%+3.8%
1.2.2. Operating Ratio

Measures how efficient Swedish Orphan Biovitrum AB (publ) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.89 means that the operating costs are kr0.89 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.894. The company is less efficient in keeping operating costs low.
  • The TTM is 0.800. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.894TTM0.800+0.094
TTM0.800YOY0.809-0.009
TTM0.8005Y0.760+0.040
5Y0.76010Y0.806-0.046

1.3. Liquidity of Swedish Orphan Biovitrum AB (publ).

1.3. Liquidity
1.3.1. Current Ratio

Measures if Swedish Orphan Biovitrum AB (publ) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.81 means the company has kr0.81 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.807. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.712. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.807TTM0.712+0.094
TTM0.712YOY0.985-0.272
TTM0.7125Y0.908-0.195
5Y0.90810Y1.500-0.593
1.3.2. Quick Ratio

Measures if Swedish Orphan Biovitrum AB (publ) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.52 means the company can pay off kr0.52 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.519. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.460. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.519TTM0.460+0.059
TTM0.460YOY0.468-0.007
TTM0.4605Y0.548-0.088
5Y0.54810Y0.749-0.201

1.4. Solvency of Swedish Orphan Biovitrum AB (publ).

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Swedish Orphan Biovitrum AB (publ) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.54 means that Swedish Orphan Biovitrum AB (publ) assets are financed with 54.4% credit (debt) and the remaining percentage (100% - 54.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 0.544. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.537. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.544TTM0.537+0.007
TTM0.537YOY0.511+0.027
TTM0.5375Y0.540-0.003
5Y0.54010Y0.456+0.084
1.4.2. Debt to Equity Ratio

Measures if Swedish Orphan Biovitrum AB (publ) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 119.5% means that company has kr1.19 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The MRQ is 1.195. The company is able to pay all its debts with equity. +1
  • The TTM is 1.195. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.195TTM1.195-0.001
TTM1.195YOY1.044+0.152
TTM1.1955Y1.194+0.001
5Y1.19410Y0.904+0.290

2. Market Valuation of Swedish Orphan Biovitrum AB (publ)

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Swedish Orphan Biovitrum AB (publ) generates.

  • Above 15 is considered overpriced but always compare Swedish Orphan Biovitrum AB (publ) to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 201.79 means the investor is paying kr201.79 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The EOD is 241.352. Based on the earnings, the company is expensive. -2
  • The MRQ is 201.789. Based on the earnings, the company is expensive. -2
  • The TTM is 78.673. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD241.352MRQ201.789+39.563
MRQ201.789TTM78.673+123.116
TTM78.673YOY40.230+38.443
TTM78.6735Y42.431+36.242
5Y42.43110Y64.028-21.597
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The EOD is 35.228. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 29.454. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -3.935. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD35.228MRQ29.454+5.775
MRQ29.454TTM-3.935+33.388
TTM-3.935YOY62.417-66.352
TTM-3.9355Y21.885-25.819
5Y21.88510Y-17.316+39.201
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Swedish Orphan Biovitrum AB (publ) is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Swedish Orphan Biovitrum AB (publ):

  • The EOD is 2.636. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.203. Based on the equity, the company is underpriced. +1
  • The TTM is 2.608. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.636MRQ2.203+0.432
MRQ2.203TTM2.608-0.404
TTM2.608YOY2.977-0.369
TTM2.6085Y3.366-0.758
5Y3.36610Y5.245-1.879
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Swedish Orphan Biovitrum AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--17.8376.896+159%2.446+629%3.818+367%2.183+717%
Book Value Per Share--101.38586.242+18%70.924+43%62.520+62%39.398+157%
Current Ratio--0.8070.712+13%0.985-18%0.908-11%1.500-46%
Debt To Asset Ratio--0.5440.537+1%0.511+7%0.540+1%0.456+19%
Debt To Equity Ratio--1.1951.1950%1.044+14%1.194+0%0.904+32%
Dividend Per Share----0%-0%-0%-0%
Eps--0.2772.038-86%1.835-85%2.038-86%1.285-78%
Free Cash Flow Per Share--1.8960.550+245%2.376-20%0.436+335%0.422+349%
Free Cash Flow To Equity Per Share---0.38312.765-103%-0.025-93%3.986-110%2.031-119%
Gross Profit Margin--1.000-1.789+279%-0.017+102%-0.142+114%-1.273+227%
Intrinsic Value_10Y_max--273.096--------
Intrinsic Value_10Y_min--38.760--------
Intrinsic Value_1Y_max--8.608--------
Intrinsic Value_1Y_min--2.074--------
Intrinsic Value_3Y_max--40.159--------
Intrinsic Value_3Y_min--7.837--------
Intrinsic Value_5Y_max--88.945--------
Intrinsic Value_5Y_min--15.313--------
Market Cap90748336537.600+16%75872673587.20075651865087.949+0%71737655330.074+6%66746844938.189+14%53410548194.089+42%
Net Profit Margin--0.0180.125-85%0.136-87%0.167-89%0.127-86%
Operating Margin--0.1060.199-47%0.171-38%0.223-52%0.185-43%
Operating Ratio--0.8940.800+12%0.809+11%0.760+18%0.806+11%
Pb Ratio2.636+16%2.2032.608-16%2.977-26%3.366-35%5.245-58%
Pe Ratio241.352+16%201.78978.673+156%40.230+402%42.431+376%64.028+215%
Price Per Share267.200+16%223.400222.750+0%211.225+6%196.530+14%157.262+42%
Price To Free Cash Flow Ratio35.228+16%29.454-3.935+113%62.417-53%21.885+35%-17.316+159%
Price To Total Gains Ratio14.980+16%12.52464.071-80%102.713-88%-13.172+205%-134.257+1172%
Quick Ratio--0.5190.460+13%0.468+11%0.548-5%0.749-31%
Return On Assets--0.0010.013-90%0.013-90%0.016-92%0.016-92%
Return On Equity--0.0030.025-89%0.026-90%0.036-92%0.031-91%
Total Gains Per Share--17.8376.896+159%2.446+629%3.818+367%2.183+717%
Usd Book Value--3236702000.0002753283500.000+18%2264248500.000+43%1995935355.900+62%1257773478.950+157%
Usd Book Value Change Per Share--1.6770.648+159%0.230+629%0.359+367%0.205+717%
Usd Book Value Per Share--9.5308.107+18%6.667+43%5.877+62%3.703+157%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0260.192-86%0.172-85%0.192-86%0.121-78%
Usd Free Cash Flow--60536000.00017554500.000+245%75858000.000-20%13909175.300+335%13472213.950+349%
Usd Free Cash Flow Per Share--0.1780.052+245%0.223-20%0.041+335%0.040+349%
Usd Free Cash Flow To Equity Per Share---0.0361.200-103%-0.002-93%0.375-110%0.191-119%
Usd Market Cap8530343634.534+16%7132031317.1977111275318.267+0%6743339601.027+6%6274203424.190+14%5020591530.244+42%
Usd Price Per Share25.117+16%21.00020.938+0%19.855+6%18.474+14%14.783+42%
Usd Profit--8836000.00065071500.000-86%58585500.000-85%65061136.500-86%40954822.400-78%
Usd Revenue--485792000.000499821500.000-3%415856000.000+17%383881392.400+27%250055510.000+94%
Usd Total Gains Per Share--1.6770.648+159%0.230+629%0.359+367%0.205+717%
 EOD+4 -4MRQTTM+18 -16YOY+15 -195Y+17 -1710Y+17 -17

3.2. Fundamental Score

Let's check the fundamental score of Swedish Orphan Biovitrum AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15241.352
Price to Book Ratio (EOD)Between0-12.636
Net Profit Margin (MRQ)Greater than00.018
Operating Margin (MRQ)Greater than00.106
Quick Ratio (MRQ)Greater than10.519
Current Ratio (MRQ)Greater than10.807
Debt to Asset Ratio (MRQ)Less than10.544
Debt to Equity Ratio (MRQ)Less than11.195
Return on Equity (MRQ)Greater than0.150.003
Return on Assets (MRQ)Greater than0.050.001
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Swedish Orphan Biovitrum AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.923
Ma 20Greater thanMa 50270.560
Ma 50Greater thanMa 100270.580
Ma 100Greater thanMa 200263.796
OpenGreater thanClose274.000
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Other Current Assets  1,255,000-878,000377,0001,839,0002,216,000-679,0001,537,000-1,538,000-1,000



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in SEK. All numbers in thousands.

Summary
Total Assets75,571,000
Total Liabilities41,138,000
Total Stockholder Equity34,433,000
 As reported
Total Liabilities 41,138,000
Total Stockholder Equity+ 34,433,000
Total Assets = 75,571,000

Assets

Total Assets75,571,000
Total Current Assets11,026,000
Long-term Assets64,545,000
Total Current Assets
Cash And Cash Equivalents 678,000
Net Receivables 6,421,000
Inventory 3,928,000
Other Current Assets -1,000
Total Current Assets  (as reported)11,026,000
Total Current Assets  (calculated)11,026,000
+/-0
Long-term Assets
Property Plant Equipment 264,000
Goodwill 10,762,000
Intangible Assets 63,317,000
Long-term Assets Other 158,000
Long-term Assets  (as reported)64,545,000
Long-term Assets  (calculated)74,501,000
+/- 9,956,000

Liabilities & Shareholders' Equity

Total Current Liabilities13,671,000
Long-term Liabilities27,467,000
Total Stockholder Equity34,433,000
Total Current Liabilities
Short-term Debt 3,389,000
Short Long Term Debt 3,249,000
Accounts payable 1,055,000
Other Current Liabilities 9,227,000
Total Current Liabilities  (as reported)13,671,000
Total Current Liabilities  (calculated)16,920,000
+/- 3,249,000
Long-term Liabilities
Long term Debt Total 17,677,000
Long term Debt 17,506,000
Capital Lease Obligations Min Short Term Debt-3,078,000
Long-term Liabilities Other 2,316,000
Long-term Liabilities  (as reported)27,467,000
Long-term Liabilities  (calculated)34,421,000
+/- 6,954,000
Total Stockholder Equity
Common Stock194,000
Retained Earnings 17,343,000
Accumulated Other Comprehensive Income 796,000
Capital Surplus 16,100,000
Total Stockholder Equity (as reported)34,433,000
Total Stockholder Equity (calculated)34,433,000
+/-0
Other
Capital Stock194,000
Cash And Equivalents678,000
Cash and Short Term Investments 678,000
Common Stock Shares Outstanding 318,799
Liabilities and Stockholders Equity 75,571,000
Net Debt 20,388,000
Net Invested Capital 55,188,000
Net Working Capital -2,645,000
Short Long Term Debt Total 21,066,000



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
2,805,530
7,328,200
7,446,700
7,454,800
7,069,600
7,031,600
7,090,500
6,944,300
6,699,533
6,775,600
6,710,800
6,556,800
6,318,426
6,567,800
6,587,600
6,505,700
6,519,320
6,223,800
6,246,000
6,370,700
6,370,744
6,606,000
6,549,000
6,673,000
8,310,718
8,538,000
9,591,000
9,794,000
9,974,139
10,332,000
10,682,000
11,075,000
10,902,907
11,386,000
12,125,000
16,266,000
17,183,157
29,972,000
30,170,000
32,795,000
45,658,000
46,431,000
42,642,000
44,134,000
48,283,000
48,192,000
46,196,000
46,732,000
48,661,000
48,809,000
48,429,000
50,933,000
52,496,000
53,911,000
75,783,000
75,571,000
75,571,00075,783,00053,911,00052,496,00050,933,00048,429,00048,809,00048,661,00046,732,00046,196,00048,192,00048,283,00044,134,00042,642,00046,431,00045,658,00032,795,00030,170,00029,972,00017,183,15716,266,00012,125,00011,386,00010,902,90711,075,00010,682,00010,332,0009,974,1399,794,0009,591,0008,538,0008,310,7186,673,0006,549,0006,606,0006,370,7446,370,7006,246,0006,223,8006,519,3206,505,7006,587,6006,567,8006,318,4266,556,8006,710,8006,775,6006,699,5336,944,3007,090,5007,031,6007,069,6007,454,8007,446,7007,328,2002,805,530000
   > Total Current Assets 
0
0
0
1,279,916
1,568,100
1,698,500
1,774,800
1,572,000
1,598,200
1,714,600
1,631,400
1,647,105
1,758,400
1,760,000
1,672,100
1,655,094
1,607,600
1,667,300
1,656,700
1,730,095
1,762,100
1,844,100
1,956,500
1,935,212
2,226,000
2,222,000
2,343,000
2,316,166
2,684,000
2,426,000
2,647,000
2,911,253
3,304,000
3,769,000
4,263,000
4,157,070
4,710,000
5,558,000
5,662,000
6,601,908
5,351,000
5,624,000
5,466,000
7,323,000
7,479,000
5,102,000
5,462,000
8,168,000
7,969,000
6,689,000
7,392,000
8,778,000
9,363,000
8,044,000
8,099,000
11,210,000
10,299,000
10,817,000
11,026,000
11,026,00010,817,00010,299,00011,210,0008,099,0008,044,0009,363,0008,778,0007,392,0006,689,0007,969,0008,168,0005,462,0005,102,0007,479,0007,323,0005,466,0005,624,0005,351,0006,601,9085,662,0005,558,0004,710,0004,157,0704,263,0003,769,0003,304,0002,911,2532,647,0002,426,0002,684,0002,316,1662,343,0002,222,0002,226,0001,935,2121,956,5001,844,1001,762,1001,730,0951,656,7001,667,3001,607,6001,655,0941,672,1001,760,0001,758,4001,647,1051,631,4001,714,6001,598,2001,572,0001,774,8001,698,5001,568,1001,279,916000
       Cash And Cash Equivalents 
0
0
0
258,280
349,100
219,900
219,000
38,500
37,700
115,000
73,100
219,043
314,100
350,000
319,200
456,951
401,200
438,100
449,300
445,097
573,700
503,200
611,300
519,147
682,000
763,000
914,000
903,660
1,108,000
770,000
824,000
785,790
1,032,000
1,189,000
1,758,000
1,478,496
1,750,000
2,306,000
2,488,000
2,998,742
463,000
1,189,000
1,077,000
737,000
842,000
213,000
164,000
404,000
633,000
233,000
212,000
1,045,000
1,063,000
360,000
288,000
1,361,000
198,000
790,000
678,000
678,000790,000198,0001,361,000288,000360,0001,063,0001,045,000212,000233,000633,000404,000164,000213,000842,000737,0001,077,0001,189,000463,0002,998,7422,488,0002,306,0001,750,0001,478,4961,758,0001,189,0001,032,000785,790824,000770,0001,108,000903,660914,000763,000682,000519,147611,300503,200573,700445,097449,300438,100401,200456,951319,200350,000314,100219,04373,100115,00037,70038,500219,000219,900349,100258,280000
       Short-term Investments 
0
0
0
48,359
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-9,000
0
0
0
000-9,00000000000000000000000000000000000000000000000000000048,359000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,130,310
1,284,000
1,457,000
1,410,000
1,523,433
1,897,000
2,067,000
1,999,000
2,165,163
3,443,000
2,267,000
1,983,000
4,625,000
4,881,000
2,743,000
2,756,000
4,525,000
4,259,000
3,154,000
3,966,000
3,439,000
3,748,000
3,127,000
3,248,000
6,141,000
6,439,000
5,954,000
6,421,000
6,421,0005,954,0006,439,0006,141,0003,248,0003,127,0003,748,0003,439,0003,966,0003,154,0004,259,0004,525,0002,756,0002,743,0004,881,0004,625,0001,983,0002,267,0003,443,0002,165,1631,999,0002,067,0001,897,0001,523,4331,410,0001,457,0001,284,0001,130,3100000000000000000000000000000000
       Other Current Assets 
0
0
0
394,879
548,300
483,900
484,800
463,100
559,300
591,000
605,100
534,243
614,500
599,500
610,600
497,775
525,200
525,800
514,100
559,048
510,000
612,000
619,700
652,130
779,000
717,000
671,000
636,652
766,000
905,000
1,025,000
1,255,417
1,284,000
1,457,000
1,410,000
1,625,306
1,896,000
2,067,000
2,000,000
2,319,054
3,443,000
2,953,000
2,766,000
4,814,000
4,882,000
2,743,000
2,756,000
4,711,000
4,260,000
3,154,000
3,965,000
4,309,000
4,935,000
4,260,000
1,255,000
377,000
2,216,000
1,537,000
-1,000
-1,0001,537,0002,216,000377,0001,255,0004,260,0004,935,0004,309,0003,965,0003,154,0004,260,0004,711,0002,756,0002,743,0004,882,0004,814,0002,766,0002,953,0003,443,0002,319,0542,000,0002,067,0001,896,0001,625,3061,410,0001,457,0001,284,0001,255,4171,025,000905,000766,000636,652671,000717,000779,000652,130619,700612,000510,000559,048514,100525,800525,200497,775610,600599,500614,500534,243605,100591,000559,300463,100484,800483,900548,300394,879000
   > Long-term Assets 
0
0
0
1,525,614
5,760,100
5,748,200
5,680,000
5,497,600
5,433,400
5,375,900
5,312,900
5,052,428
5,017,200
4,950,800
4,884,700
4,663,332
4,960,200
4,920,300
4,849,000
4,789,225
4,461,700
4,401,900
4,414,200
4,435,532
4,380,000
4,327,000
4,330,000
5,994,552
5,854,000
7,165,000
7,147,000
7,062,886
7,028,000
6,913,000
6,812,000
6,745,837
6,676,000
6,567,000
10,604,000
10,581,249
24,621,000
24,546,000
27,329,000
38,335,000
38,952,000
37,540,000
38,672,000
40,115,000
40,223,000
39,507,000
39,340,000
39,883,000
39,446,000
40,385,000
42,834,000
41,285,000
43,613,000
64,966,000
64,545,000
64,545,00064,966,00043,613,00041,285,00042,834,00040,385,00039,446,00039,883,00039,340,00039,507,00040,223,00040,115,00038,672,00037,540,00038,952,00038,335,00027,329,00024,546,00024,621,00010,581,24910,604,0006,567,0006,676,0006,745,8376,812,0006,913,0007,028,0007,062,8867,147,0007,165,0005,854,0005,994,5524,330,0004,327,0004,380,0004,435,5324,414,2004,401,9004,461,7004,789,2254,849,0004,920,3004,960,2004,663,3324,884,7004,950,8005,017,2005,052,4285,312,9005,375,9005,433,4005,497,6005,680,0005,748,2005,760,1001,525,614000
       Property Plant Equipment 
0
0
0
251,963
270,400
5,693,000
262,200
251,400
240,400
230,900
219,300
155,941
5,009,600
140,300
135,800
125,586
123,900
123,200
119,600
125,780
120,100
118,200
115,800
115,230
110,000
107,000
105,000
108,576
101,000
111,000
107,000
121,023
126,000
126,000
122,000
134,182
133,000
135,000
135,000
136,299
539,000
488,000
508,000
519,000
514,000
594,000
564,000
535,000
516,000
491,000
481,000
493,000
380,000
360,000
309,000
274,000
270,000
307,000
264,000
264,000307,000270,000274,000309,000360,000380,000493,000481,000491,000516,000535,000564,000594,000514,000519,000508,000488,000539,000136,299135,000135,000133,000134,182122,000126,000126,000121,023107,000111,000101,000108,576105,000107,000110,000115,230115,800118,200120,100125,780119,600123,200123,900125,586135,800140,3005,009,600155,941219,300230,900240,400251,400262,2005,693,000270,400251,963000
       Goodwill 
0
0
0
0
1,634,800
0
0
0
0
0
0
0
0
0
0
1,605,307
0
0
0
1,648,307
0
0
0
1,554,158
0
0
0
1,554,158
0
0
0
1,554,158
1,554,000
1,554,000
1,554,000
1,554,158
1,554,000
1,554,000
1,554,000
1,554,158
1,554,000
1,554,000
2,551,000
6,678,000
6,779,000
6,413,000
6,256,000
5,873,000
6,099,000
6,006,000
6,141,000
6,288,000
6,398,000
6,861,000
7,304,000
7,007,000
6,975,000
10,818,000
10,762,000
10,762,00010,818,0006,975,0007,007,0007,304,0006,861,0006,398,0006,288,0006,141,0006,006,0006,099,0005,873,0006,256,0006,413,0006,779,0006,678,0002,551,0001,554,0001,554,0001,554,1581,554,0001,554,0001,554,0001,554,1581,554,0001,554,0001,554,0001,554,1580001,554,1580001,554,1580001,648,3070001,605,30700000000001,634,8000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,956
0
0
0
35,155
0
193,000
227,000
55,440
242,000
447,000
444,000
404,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000404,000444,000447,000242,00055,440227,000193,000035,1550001,9560000000000000000000000000000000
       Intangible Assets 
0
0
0
1,159,144
3,799,200
0
5,382,600
5,224,300
5,172,100
5,125,000
5,070,900
4,885,077
0
0
0
2,928,059
0
0
0
2,988,721
0
0
0
2,693,330
0
0
0
4,232,877
0
0
0
5,251,852
5,193,000
5,089,000
4,981,000
4,890,913
4,789,000
4,686,000
8,688,000
8,604,518
22,286,000
22,057,000
23,826,000
30,736,000
31,239,000
36,361,000
30,984,000
32,918,000
32,879,000
32,271,000
32,040,000
32,135,000
31,866,000
39,112,000
34,189,000
33,006,000
35,368,000
63,673,000
63,317,000
63,317,00063,673,00035,368,00033,006,00034,189,00039,112,00031,866,00032,135,00032,040,00032,271,00032,879,00032,918,00030,984,00036,361,00031,239,00030,736,00023,826,00022,057,00022,286,0008,604,5188,688,0004,686,0004,789,0004,890,9134,981,0005,089,0005,193,0005,251,8520004,232,8770002,693,3300002,988,7210002,928,0590004,885,0775,070,9005,125,0005,172,1005,224,3005,382,60003,799,2001,159,144000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
133,897
155,000
144,000
155,000
131,429
200,000
-2,000
0
412,774
1,000
0
-1,000
847,000
369,000
1,000
698,000
1,204,000
541,000
556,000
490,000
1,338,000
802,000
840,000
933,000
1,000
-1,000
858,000
806,000
806,000858,000-1,0001,000933,000840,000802,0001,338,000490,000556,000541,0001,204,000698,0001,000369,000847,000-1,00001,000412,7740-2,000200,000131,429155,000144,000155,000133,8970000000000000000000000000000000
> Total Liabilities 
0
0
0
1,452,735
2,900,600
2,992,500
3,018,800
2,727,200
2,757,200
2,106,400
1,996,000
1,736,106
1,681,100
1,670,400
1,570,400
1,480,429
1,727,700
1,760,900
1,731,100
1,750,076
1,780,700
1,770,600
1,837,800
1,847,874
1,961,000
1,877,000
2,032,000
3,621,374
3,522,000
4,344,000
4,424,000
4,619,861
4,740,000
4,715,000
4,723,000
4,202,383
4,171,000
4,273,000
7,767,000
8,143,060
15,492,000
15,198,000
17,108,000
28,728,000
27,776,000
24,020,000
25,350,000
28,077,000
27,328,000
25,023,000
24,990,000
25,458,000
25,052,000
24,103,000
25,868,000
25,971,000
26,083,000
47,408,000
41,138,000
41,138,00047,408,00026,083,00025,971,00025,868,00024,103,00025,052,00025,458,00024,990,00025,023,00027,328,00028,077,00025,350,00024,020,00027,776,00028,728,00017,108,00015,198,00015,492,0008,143,0607,767,0004,273,0004,171,0004,202,3834,723,0004,715,0004,740,0004,619,8614,424,0004,344,0003,522,0003,621,3742,032,0001,877,0001,961,0001,847,8741,837,8001,770,6001,780,7001,750,0761,731,1001,760,9001,727,7001,480,4291,570,4001,670,4001,681,1001,736,1061,996,0002,106,4002,757,2002,727,2003,018,8002,992,5002,900,6001,452,735000
   > Total Current Liabilities 
0
0
0
748,542
939,500
834,700
882,400
757,200
800,700
652,400
579,000
676,703
716,400
608,900
518,000
508,800
614,600
643,400
619,600
647,434
712,500
686,000
730,200
746,984
862,000
784,000
906,000
1,320,102
1,263,000
1,382,000
1,490,000
1,758,094
2,022,000
2,192,000
2,341,000
2,364,818
2,491,000
2,780,000
6,550,000
6,951,070
7,603,000
7,517,000
4,161,000
5,741,000
5,764,000
5,283,000
7,004,000
10,443,000
10,330,000
7,952,000
7,910,000
8,761,000
9,056,000
7,882,000
9,173,000
14,857,000
14,713,000
18,387,000
13,671,000
13,671,00018,387,00014,713,00014,857,0009,173,0007,882,0009,056,0008,761,0007,910,0007,952,00010,330,00010,443,0007,004,0005,283,0005,764,0005,741,0004,161,0007,517,0007,603,0006,951,0706,550,0002,780,0002,491,0002,364,8182,341,0002,192,0002,022,0001,758,0941,490,0001,382,0001,263,0001,320,102906,000784,000862,000746,984730,200686,000712,500647,434619,600643,400614,600508,800518,000608,900716,400676,703579,000652,400800,700757,200882,400834,700939,500748,542000
       Short-term Debt 
0
0
0
50,000
775,200
670,400
882,400
757,200
800,700
652,400
579,000
0
716,400
595,200
503,700
0
700
1,300
1,600
0
1,800
1,900
1,700
0
2,000
2,000
2,000
20,000
1,000
2,000
2,000
496,697
2,000
2,000
2,000
579,895
6,000
7,000
0
0
82,000
84,000
90,000
99,000
102,000
111,000
2,219,000
4,126,000
4,208,000
2,137,000
2,154,000
1,882,000
1,149,000
1,453,000
1,825,000
5,929,000
6,067,000
10,695,000
3,389,000
3,389,00010,695,0006,067,0005,929,0001,825,0001,453,0001,149,0001,882,0002,154,0002,137,0004,208,0004,126,0002,219,000111,000102,00099,00090,00084,00082,000007,0006,000579,8952,0002,0002,000496,6972,0002,0001,00020,0002,0002,0002,00001,7001,9001,80001,6001,3007000503,700595,200716,4000579,000652,400800,700757,200882,400670,400775,20050,000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
502,216
504,000
504,000
505,000
5,044
6,000
7,000
0
0
82,000
84,000
0
0
0
0
2,108,000
4,015,000
4,095,000
2,025,000
2,040,000
1,768,000
1,024,000
1,321,000
1,689,000
5,795,000
5,933,000
10,542,000
3,249,000
3,249,00010,542,0005,933,0005,795,0001,689,0001,321,0001,024,0001,768,0002,040,0002,025,0004,095,0004,015,0002,108,000000084,00082,000007,0006,0005,044505,000504,000504,000502,2160000000000000000000000000000000
       Accounts payable 
0
0
0
243,899
0
0
0
0
0
0
0
287,971
0
0
0
104,488
0
0
0
239,098
0
0
0
235,972
0
0
0
183,193
0
0
0
280,173
0
0
0
358,449
0
0
0
486,972
743,000
419,000
347,000
681,000
487,000
456,000
414,000
569,000
392,000
434,000
795,000
558,000
545,000
519,000
361,000
1,252,000
625,000
933,000
1,055,000
1,055,000933,000625,0001,252,000361,000519,000545,000558,000795,000434,000392,000569,000414,000456,000487,000681,000347,000419,000743,000486,972000358,449000280,173000183,193000235,972000239,098000104,488000287,9710000000243,899000
       Other Current Liabilities 
0
0
0
454,643
164,300
164,300
0
0
0
0
0
388,732
0
13,700
14,300
404,312
613,900
642,100
618,000
408,336
710,700
684,100
728,500
511,012
860,000
782,000
904,000
1,116,909
1,262,000
1,380,000
1,488,000
981,224
2,020,000
2,190,000
2,339,000
1,426,474
2,491,000
2,780,000
6,550,000
6,464,098
6,778,000
7,014,000
3,724,000
4,961,000
5,175,000
4,716,000
4,371,000
5,748,000
5,730,000
5,381,000
4,961,000
6,017,000
7,362,000
5,910,000
6,987,000
4,545,000
8,021,000
6,759,000
9,227,000
9,227,0006,759,0008,021,0004,545,0006,987,0005,910,0007,362,0006,017,0004,961,0005,381,0005,730,0005,748,0004,371,0004,716,0005,175,0004,961,0003,724,0007,014,0006,778,0006,464,0986,550,0002,780,0002,491,0001,426,4742,339,0002,190,0002,020,000981,2241,488,0001,380,0001,262,0001,116,909904,000782,000860,000511,012728,500684,100710,700408,336618,000642,100613,900404,31214,30013,7000388,73200000164,300164,300454,643000
   > Long-term Liabilities 
0
0
0
704,193
1,961,100
2,157,800
2,136,400
1,970,000
1,956,500
1,454,000
1,417,000
1,059,403
964,700
1,061,500
1,052,400
971,629
1,113,100
1,117,500
1,111,500
1,102,642
1,068,200
1,084,600
1,107,600
1,100,890
1,099,000
1,093,000
1,126,000
2,301,272
2,259,000
2,962,000
2,934,000
2,861,767
2,718,000
2,523,000
2,382,000
1,837,565
1,680,000
1,493,000
1,217,000
1,191,990
7,889,000
7,681,000
12,947,000
22,987,000
22,012,000
18,737,000
18,346,000
17,634,000
16,998,000
17,071,000
17,080,000
16,697,000
15,996,000
16,221,000
16,695,000
11,114,000
11,370,000
29,021,000
27,467,000
27,467,00029,021,00011,370,00011,114,00016,695,00016,221,00015,996,00016,697,00017,080,00017,071,00016,998,00017,634,00018,346,00018,737,00022,012,00022,987,00012,947,0007,681,0007,889,0001,191,9901,217,0001,493,0001,680,0001,837,5652,382,0002,523,0002,718,0002,861,7672,934,0002,962,0002,259,0002,301,2721,126,0001,093,0001,099,0001,100,8901,107,6001,084,6001,068,2001,102,6421,111,5001,117,5001,113,100971,6291,052,4001,061,500964,7001,059,4031,417,0001,454,0001,956,5001,970,0002,136,4002,157,8001,961,100704,193000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,445,000
9,501,000
9,682,000
9,563,000
9,024,000
8,624,000
8,400,000
8,358,000
3,171,000
3,167,000
17,487,000
17,677,000
17,677,00017,487,0003,167,0003,171,0008,358,0008,400,0008,624,0009,024,0009,563,0009,682,0009,501,00010,445,00000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,359,551
2,216,000
2,021,000
1,879,000
1,832,521
1,675,000
1,488,000
1,213,000
1,188,999
1,560,000
1,792,000
3,968,000
6,526,000
6,668,000
6,357,000
7,251,000
7,189,000
7,497,000
7,389,000
7,517,000
7,673,000
7,372,000
7,821,000
8,337,000
7,943,000
8,203,000
0
0
008,203,0007,943,0008,337,0007,821,0007,372,0007,673,0007,517,0007,389,0007,497,0007,189,0007,251,0006,357,0006,668,0006,526,0003,968,0001,792,0001,560,0001,188,9991,213,0001,488,0001,675,0001,832,5211,879,0002,021,0002,216,0002,359,5510000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
181,940
0
0
0
492,000
0
0
0
546,000
0
0
0
517,000
0
0
0
0
0
0
0
0000000517,000000546,000000492,000000181,940000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
1,352,795
4,427,600
4,454,200
4,436,000
4,342,400
4,274,400
4,984,100
4,948,300
4,963,427
5,094,500
5,040,400
4,986,400
4,837,997
4,840,100
4,826,700
4,774,600
4,769,244
4,443,100
4,475,400
4,532,900
4,522,870
4,645,000
4,672,000
4,640,000
4,689,344
5,016,000
5,247,000
5,370,000
5,354,278
5,592,000
5,967,000
6,352,000
6,700,524
7,215,000
7,851,000
8,499,000
9,040,097
14,481,000
14,972,000
15,686,000
16,930,000
18,654,000
18,622,000
18,784,000
20,206,000
20,864,000
21,174,000
21,743,000
23,203,000
23,757,000
24,326,000
25,065,000
26,525,000
27,828,000
28,375,000
34,433,000
34,433,00028,375,00027,828,00026,525,00025,065,00024,326,00023,757,00023,203,00021,743,00021,174,00020,864,00020,206,00018,784,00018,622,00018,654,00016,930,00015,686,00014,972,00014,481,0009,040,0978,499,0007,851,0007,215,0006,700,5246,352,0005,967,0005,592,0005,354,2785,370,0005,247,0005,016,0004,689,3444,640,0004,672,0004,645,0004,522,8704,532,9004,475,4004,443,1004,769,2444,774,6004,826,7004,840,1004,837,9974,986,4005,040,4005,094,5004,963,4274,948,3004,984,1004,274,4004,342,4004,436,0004,454,2004,427,6001,352,795000
   Common Stock
0
0
0
27,936
0
0
0
4,342,400
0
0
0
146,664
0
0
0
147,948
0
0
0
148,362
0
0
0
148,580
0
0
0
149,150
0
0
0
149,254
5,592,000
5,967,000
6,352,000
149,527
7,215,000
7,851,000
8,499,000
149,974
14,481,000
14,972,000
15,686,000
165,000
18,654,000
18,622,000
18,784,000
167,000
20,864,000
21,174,000
21,743,000
169,000
23,757,000
24,326,000
25,065,000
170,000
170,000
171,000
194,000
194,000171,000170,000170,00025,065,00024,326,00023,757,000169,00021,743,00021,174,00020,864,000167,00018,784,00018,622,00018,654,000165,00015,686,00014,972,00014,481,000149,9748,499,0007,851,0007,215,000149,5276,352,0005,967,0005,592,000149,254000149,150000148,580000148,362000147,948000146,6640004,342,40000027,936000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
351,000
434,000
866,000
796,000
796,000866,000434,000351,0000000000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,197,000
10,089,000
16,100,000
16,100,00010,089,00010,197,00000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
1,233,603
0
0
0
0
0
0
0
4,812,031
0
0
0
4,793,157
0
0
0
4,811,687
0
0
0
4,833,145
0
0
0
4,931,226
0
0
0
4,816,225
0
0
0
5,003,171
0
0
0
4,924,949
0
0
0
9,496,000
18,654,000
18,622,000
18,784,000
9,562,000
20,864,000
21,174,000
21,743,000
9,879,000
23,757,000
24,326,000
25,065,000
10,211,000
10,197,000
10,090,000
16,100,000
16,100,00010,090,00010,197,00010,211,00025,065,00024,326,00023,757,0009,879,00021,743,00021,174,00020,864,0009,562,00018,784,00018,622,00018,654,0009,496,0000004,924,9490005,003,1710004,816,2250004,931,2260004,833,1450004,811,6870004,793,1570004,812,03100000001,233,603000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue22,123,000
Cost of Revenue-4,915,000
Gross Profit22,123,00017,208,000
 
Operating Income (+$)
Gross Profit22,123,000
Operating Expense-11,952,000
Operating Income22,123,00010,171,000
 
Operating Expense (+$)
Research Development2,582,000
Selling General Administrative9,286,000
Selling And Marketing Expenses-
Operating Expense11,952,00011,868,000
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-878,000
Net Interest Income-878,000
 
Pretax Income (+$)
Operating Income22,123,000
Net Interest Income-878,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)3,483,00023,012,000
EBIT - interestExpense = 4,336,000
3,483,000
2,769,000
Interest Expense-
Earnings Before Interest and Taxes (EBIT)4,336,0003,483,000
Earnings Before Interest and Taxes (EBITDA)22,123,000
 
After tax Income (+$)
Income Before Tax3,483,000
Tax Provision-714,000
Net Income From Continuing Ops2,769,0002,769,000
Net Income2,769,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses16,867,000
Total Other Income/Expenses Net-889,000878,000
 

Technical Analysis of Swedish Orphan Biovitrum AB (publ)
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Swedish Orphan Biovitrum AB (publ). The general trend of Swedish Orphan Biovitrum AB (publ) is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Swedish Orphan Biovitrum AB (publ)'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Swedish Orphan Biovitrum AB (publ).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 283.80 < 302.00.

The bearish price targets are: 260.60 > 252.00 > 243.20.

Tweet this
Swedish Orphan Biovitrum AB (publ) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Swedish Orphan Biovitrum AB (publ). The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Swedish Orphan Biovitrum AB (publ) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Swedish Orphan Biovitrum AB (publ). The current macd is 0.38552099.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Swedish Orphan Biovitrum AB (publ) price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Swedish Orphan Biovitrum AB (publ). This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Swedish Orphan Biovitrum AB (publ) price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Swedish Orphan Biovitrum AB (publ) Daily Moving Average Convergence/Divergence (MACD) ChartSwedish Orphan Biovitrum AB (publ) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Swedish Orphan Biovitrum AB (publ). The current adx is 15.52.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Swedish Orphan Biovitrum AB (publ) shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Swedish Orphan Biovitrum AB (publ) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Swedish Orphan Biovitrum AB (publ). The current sar is 278.09.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Swedish Orphan Biovitrum AB (publ) Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Swedish Orphan Biovitrum AB (publ). The current rsi is 47.92. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Swedish Orphan Biovitrum AB (publ) Daily Relative Strength Index (RSI) ChartSwedish Orphan Biovitrum AB (publ) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Swedish Orphan Biovitrum AB (publ). The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Swedish Orphan Biovitrum AB (publ) price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Swedish Orphan Biovitrum AB (publ) Daily Stochastic Oscillator ChartSwedish Orphan Biovitrum AB (publ) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Swedish Orphan Biovitrum AB (publ). The current cci is -9.24635257.

Swedish Orphan Biovitrum AB (publ) Daily Commodity Channel Index (CCI) ChartSwedish Orphan Biovitrum AB (publ) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Swedish Orphan Biovitrum AB (publ). The current cmo is -8.05489768.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Swedish Orphan Biovitrum AB (publ) Daily Chande Momentum Oscillator (CMO) ChartSwedish Orphan Biovitrum AB (publ) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Swedish Orphan Biovitrum AB (publ). The current willr is -71.55172414.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Swedish Orphan Biovitrum AB (publ) is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Swedish Orphan Biovitrum AB (publ) Daily Williams %R ChartSwedish Orphan Biovitrum AB (publ) Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Swedish Orphan Biovitrum AB (publ).

Swedish Orphan Biovitrum AB (publ) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Swedish Orphan Biovitrum AB (publ). The current atr is 6.84540896.

Swedish Orphan Biovitrum AB (publ) Daily Average True Range (ATR) ChartSwedish Orphan Biovitrum AB (publ) Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Swedish Orphan Biovitrum AB (publ). The current obv is 12,199,526.

Swedish Orphan Biovitrum AB (publ) Daily On-Balance Volume (OBV) ChartSwedish Orphan Biovitrum AB (publ) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Swedish Orphan Biovitrum AB (publ). The current mfi is 26.77.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Swedish Orphan Biovitrum AB (publ) Daily Money Flow Index (MFI) ChartSwedish Orphan Biovitrum AB (publ) Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Swedish Orphan Biovitrum AB (publ).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Swedish Orphan Biovitrum AB (publ) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Swedish Orphan Biovitrum AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.923
Ma 20Greater thanMa 50270.560
Ma 50Greater thanMa 100270.580
Ma 100Greater thanMa 200263.796
OpenGreater thanClose274.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Swedish Orphan Biovitrum AB (publ) with someone you think should read this too:
  • Are you bullish or bearish on Swedish Orphan Biovitrum AB (publ)? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Swedish Orphan Biovitrum AB (publ)? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Swedish Orphan Biovitrum AB (publ)

I send you an email if I find something interesting about Swedish Orphan Biovitrum AB (publ).


Comments

How you think about this?

Leave a comment

Stay informed about Swedish Orphan Biovitrum AB (publ).

Receive notifications about Swedish Orphan Biovitrum AB (publ) in your mailbox!